Simplified molecular input line entry system-based optimal descriptors: QSAR modelling for voltage-gated potassium channel subunit Kv7.2

SAR and QSAR in Environmental Research

Volumn 25, Issue 1, 2014, Pages 73-90

  Achary, P Ganga Raju ^a  

^a SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

optimal descriptor; QSAR; SMILES; voltage gated potassium channel

Indexed keywords

BINDING ENERGY; COMPUTATIONAL CHEMISTRY; MOLECULAR GRAPHICS; POTASSIUM;

BINDING AFFINITIES; DECIMAL LOGARITHMS; EFFECTIVE CONCENTRATION; ENTRY SYSTEM; MODEL-BASED OPC; OPTIMAL DESCRIPTOR; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP MODELING; SIMPLIFIED MOLECULAR INPUT LINE ENTRY SYSTEM; VOLTAGE-GATED POTASSIUM CHANNELS;

QUANTUM CHEMISTRY;

POTASSIUM CHANNEL KCNQ2;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; MONTE CARLO METHOD; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

KCNQ2 POTASSIUM CHANNEL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONTE CARLO METHOD; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE;

EID: 84896699257     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2013.842930     Document Type: Article

References (33)

1. D.A. Brown, S.A. Hughes, S.J. Marsh, and A. Tinker, Regulation of M(Kv7.2/7.3) channels in neurons by PIP2 and products of PIP2 hydrolysis: Significance for receptor-mediated inhibition, J. Physiol.(Oxford, U. K.) 582(2007), pp. 917-925.
2. J.F. Otto, Y. Yang, W.N. Frankel, H.S. White, and K.S. Wilcox, A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons, J. Neurosci. 26 (2006), pp. 2053-2059.
3. T.V. Wuttke, G. Seebohm, S. Bail, S. Maljevic, and H. Lerche, The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate, Mol. Pharmacol. 67 (2005), pp. 1009-1017.
4. F.M. Ashcroft, From molecule to malady, Nature 440 (2006), pp. 440-447.
5. D.A. Doyle, Structural changes during ion channel gating, Trends Neurosci. 27 (2004), pp. 298-302.
6. C.X. Gu, P.F. Juranka, and C.E. Morris, Stretch-activation and stretch-inactivation of Shaker-IR, a voltage-gated K+ channel, Biophys. J. 80 (2001), pp. 2678-2693.
7. S. Isomoto and Y. Kurachi, Molecular and biophysical aspects of potassium channels, Nippon Rinsho 54 (1996), pp. 660-666.
8. T.S. Surti and L.Y. Jan, A potassium channel, the M-channel, as a therapeutic target, Curr. Opin. Invest. Drugs 6 (2005), pp. 704-71.
9. J. Robbins, KCNQ potassium channels: Physiology, pathophysiology, and pharmacology, Pharmacol. Ther. 90 (2001), pp. 1-19.
10. T.J. Jentsch, Neuronal KCNQ potassium channels: Physiology and role in disease, Nat. Rev. Neurosci. 1 (2000), pp. 21-30.
11. K. Lawson and N.G. McKay, Modulation of potassium channels as a therapeutic approach, Curr. Pharm. Des. 12 (2006), pp. 459-470.
12. Organisation for Economic Co-operation and Development (OECD)Available at: http://www.oecd.org/dataoecd/33/37/37849783.pdf.
13. Coral 1.5, 2010, softwareavailable at http://www.insilico.eu/coral.
14. J. García, P.R. Duchowicz, M.F. Rozas, J.A. Caram, M.V. Mirífico, F.M. Fernández, and E.A. Castro, A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases, J. Mol. Graphics Model. 31 (2011), pp. 10-19.
15. A.P. Toropova, A.A. Toropov, E. Benfenati, G. Gini, D. Leszczynska, and J. Leszczynski, QSAR modeling of measured binding affinity for fullerene-based HIV-1 PR inhibitors by CORAL, J. Math. Chem. 47 (2010), pp. 959-987.
16. E. Benfenati, A.A. Toropov, A.P. Toropova, A. Manganaro, and R. Gonella Diaza, CORAL Software: QSAR for anticancer agents, Chem. Biol. Drug Des. 77 (2011), pp. 471-476.
17. E. Ibezim, P.R. Duchowicz, E.V. Ortiz, and E.A. Castro, QSAR on aryl-piperazine derivatives with activity on malaria, Chemom. Intell. Lab. Syst. 110 (2012), pp. 81-88.
18. A.M. Doweyko, 3D-QSAR illusions, J. Comput.-Aided Mol. Des. 18(2004), pp. 587-596.
19. A.M. Doweyko QSAR: Dead or alive? J. Comput.-Aided Mol. Des. 22 (2008), pp. 81-89.
20. S.R. Johnson, The trouble with QSAR, or how I learned to stop worrying and embrace fallacy, J. Chem. Inf. Model. 48 (2008), pp. 25-26.
21. X. Chen, Y. Lin, M. Liu, and M.K. Gilson, The binding database: Data management and interface design, Bioinformatics 18 (2002), pp. 130-139.
22. T. Liu, Y. Lin, X. Wen, R.N. Jorrisen, and M.K. Gilson, BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities, Nucleic Acids Res. 35 (2007), pp. D198-201.
23. Spartan 10 software, obtained from Wavefunction Inc; software available at http://www.wavefun.com/products/spartan.html
24. P.P. Roy and K. Roy, QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors, Chem. Biol. Drug Des. 73 (2009), pp. 442-455.
25. P.K. Ojha, and K. Roy, Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection, Chemom. Intell. Lab. Syst. 109 (2011), pp. 146-161.
26. A. Golbraikh and A. Tropsh, Beware of q2!, J. Mol. Graphics Modell. 20 (2002), pp. 269-276.
27. P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring rm2 metrics for validation of QSPR models, Chemom. Intell. Lab. Syst. 107 (2011), 194-205.
28. Y. Takahashi, S. Hibi, Y. Hoshino, K. Kikuchi, K. Shin, K. Murata-Tai, M. Fujisawa, M. Ino, H. Shibata, and M. Yonaga, Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor, J. Med. Chem. 55 (2012), pp. 5255-5269.
29. J.E. Dowling, M. Alimzhanov, L. Bao, M.H. Block, C. Chuaqui, E.L. Cooke, C.R. Denz, A. Hird, S. Huang, N.A. Larsen, et al. Structure and property based design of pyrazolo[1,5-a]pyrimidine inhibitors of CK2 kinase with activity in vivo. Preprint to appear (2013) in ACS Med. Chem. Lett. Available at http://pubs.acs.org/doi/abs/10.1021/ml400197u
30. E. Cichero, C. Casolino, G. Menozzi, L. Mosti, and P. Fossa, Exploring the qsar of pyrazolo[3,4-b]pyridine, pyrazolo[3,4-b]pyridone and pyrazolo[3,4-b]pyrimidine derivatives as antagonists for a1 adenosine receptor, QSAR Comb. Sci. 28 (2009), pp. 426-435.
31. K. Roy, QSAR of adenosine receptor antagonists II: QSAR Comb, Sci. 22 (2003), pp. 614-621.
32. Q. Jinlong, Z. Fan, M. Yi, F. Yan, X. Wen, Z. Diqun, W. Yibing, D. Xiaona, J. Qingzhong, W. Kewei, and Z. Hailin, Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators, Eur. J. Med. Chem. 46 (2011), pp. 934-943.
33. S.L. Cheong, G. Venkatesan, P. Paira, R. Jothibasu, A.L. Mandel, S. Federico, G. Spalluto, and G. Pastorin, Pyrazolo derivatives as potent adenosine receptor antagonists: An overview on the structure-activity relationships, Int. J. Med. Chem. 2011 (2011), pp. 1-15. Available at http://www.hindawi.com/journals/ijmc/2011/480652/